|
1）Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases: Position Paper on acute liver failure 2011. Hepatology. 2012; 55: 965-7
|
|
|
|
2）Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011; 41: 805-12
|
|
|
|
|
3）Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification and prediction of the outcome. J Gastroenterol. 2012; 47: 849-61
|
|
|
|
|
|
4）Oketani M, Ido A, Uto H, et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2011; 41: 805-12
|
|
|
|
|
|
5）坪内博仁，熊田博光，清澤研道，他．免疫抑制・化学療法により発症するB型肝炎対策－厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告－．肝臓．2009; 50: 38-42
|
|
|
|
|
6）Schiodt FV, Chung RT, Schilsky ML, et al. Outcome of acute liver failure in the elderly. Liver Transpl. 2009; 15: 1481-7
|
|
|
|
|
|
7）坪内博仁，桶谷 真，井戸章雄，他．劇症肝炎及び遅発性肝不全（LOHF：late onset hepatic failure）の全国集計（2009年）．厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究．平成22年度研究報告書．2011.p.96-113
|
|
|
|
|
|
8）持田 智，中山伸朗．我が国における急性肝不全および遅発性肝不全の実態（2010年）―平成23年度全国調査―．厚生労働科学研究費補助金難治性疾患克服研究事業 難治性の肝・胆道疾患に関する調査研究．平成23年度研究報告書．2012.p.101-12
|
|
|
|
|
|
9）Yamashiki N, Sugawara Y, Tamura S, et al. Outcome after living donor liver transplantation for acute liver failure in Japan; results of a nationwide survey. Liver Transpl. 2012; 18: 1069-77
|
|
|
|
|
|
10）Evens AM, Jovanovic BD, Su YC, et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.Ann Oncol. 2011; 22: 1170-80
|
|
|
|
|
|
11）Kusumoto S, Tanaka Y, Ueda R, et al.Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.J Gastroenterol. 2011; 46: 9-16
|
|
|
|
|
|
12）Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005; 74: 254-8
|
|
|
|
|
|
13）Sugauchi F, Tanaka Y, Kusumoto S, et al.Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011; 83: 412-8
|
|
|
|
|
|
14）Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection.Expert Opin Biol Ther. 2011; 11: 533-44
|
|
|
|
|
|
15）Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol Res. 2012; 42: 333-9
|
|
|
|
|
|
16）Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-2
|
|
|
|
|
|
17）European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85
|
|
|
|
|
|
18）Marzano A, Angelucci E, Andreone P, et al.Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007; 39: 397-408
|
|
|
|
|
|
19）Marignani M, Gigante E, Begini P, et al. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol. 2012; 4: 37-45
|
|
|
|
|
|
20）Mastroianni CM, Lichtner M, Citton R, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011; 17: 3881-7
|
|
|
|
|